검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | (F-18)-DCFPyL (F-18, (F-18)-DCFPyL) Progenics Pharmaceuticals, Inc.·Metastatic Renal Cell Carcinoma ORR 100% |
|---|---|
Overview Program | (F-18)-DCFPyL |
Overview Company | Progenics Pharmaceuticals, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Metastatic Renal Cell Carcinoma |
Overview Indication | Metastatic Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | target proteins, pathway |
MoA Biomarker | PD-L1) expression |
PK/PD Species | NHP, Rat |
PK/PD Animal (cat.) | Rat, NHP, In vitro |
PK/PD Experiment | PD |
Toxicology Species | NHP, Rat |
Toxicology Animal (cat.) | Rat, NHP, In vitro |
Toxicology Major finding | Biodistribution, radiodosimetry and pharmacokinetics of [ 18 F]GSK1482160 for cerebral P2X7 receptor in living subjects.. BACKGROUND: Increasing evidence of the role of neuroinflammation in pathophysiology has highlighted the importance of P2X7 receptor (P2X7R)-targeted neurodegeneration diseases. The safety, biodistribution, pharmacokinetics and dosimetry of a promising F-18-labeled PET tracer [1… |
Clinical Primary efficacy | ORR 100% |
Clinical ORR | 100% |
Clinical Result source | ClinicalTrials.gov NCT02680041 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | (F-18)-DCFPyL (F-18, (F-18)-DCFPyL) Progenics Pharmaceuticals, Inc.·Metastatic Renal Cell Carcinoma ORR 100% |
|---|---|
Overview Program | (F-18)-DCFPyL |
Overview Company | Progenics Pharmaceuticals, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Metastatic Renal Cell Carcinoma |
Overview Indication | Metastatic Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | target proteins, pathway |
MoA Biomarker | PD-L1) expression |
PK/PD Species | NHP, Rat |
PK/PD Animal (cat.) | Rat, NHP, In vitro |
PK/PD Experiment | PD |
Toxicology Species | NHP, Rat |
Toxicology Animal (cat.) | Rat, NHP, In vitro |
Toxicology Major finding | Biodistribution, radiodosimetry and pharmacokinetics of [ 18 F]GSK1482160 for cerebral P2X7 receptor in living subjects.. BACKGROUND: Increasing evidence of the role of neuroinflammation in pathophysiology has highlighted the importance of P2X7 receptor (P2X7R)-targeted neurodegeneration diseases. The safety, biodistribution, pharmacokinetics and dosimetry of a promising F-18-labeled PET tracer [1… |
Clinical Primary efficacy | ORR 100% |
Clinical ORR | 100% |
Clinical Result source | ClinicalTrials.gov NCT02680041 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교